Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV

Please use this identifier to cite or link to this item: http://ir.mu.ac.ke:8080/jspui/handle/123456789/6264

Full metadata record

DC Field	Value	Language
dc.contributor.author	Siika, Abraham	-
dc.date.accessioned	2022-04-20T09:49:03Z	-
dc.date.available	2022-04-20T09:49:03Z	-
dc.date.issued	2021	-
dc.identifier.uri	https://www.nejm.org/doi/full/10.1056/NEJMoa2101609	-
dc.identifier.uri	http://ir.mu.ac.ke:8080/jspui/handle/123456789/6264	-
dc.description.abstract	The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this regimen when NRTIs are predicted to lack activity because of drug resistance, as well as for the recommended switch of an NRTI from tenofovir to zidovudine	en_US
dc.language.iso	en	en_US
dc.publisher	The New England Journal of Medicine	en_US
dc.subject	HIV	en_US
dc.title	Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV	en_US
dc.type	Article	en_US
Appears in Collections:	School of Medicine

Files in This Item:

File	Description	Size	Format
nejmoa2101609.pdf		666.63 kB	Adobe PDF	View/Open